Market Research Logo

Global Critical Care Therapeutics Market 2017-2021

Global Critical Care Therapeutics Market 2017-2021

About Critical Care Therapeutics

Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.

Technavio’s analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • CSL Behring
  • Grifols
  • Kedrion Biopharma
  • Octapharma
  • Shire
Other prominent vendors
  • Abeona Therapeutics
  • ADMA Biologics
  • Albumedix
  • Armetheon
  • Asklepios BioPharmaceutical
  • Aspen Pharma
  • Baxter
  • Bayer HealthCare
  • Bio Products Laboratory
  • BioDelivery Sciences
  • Biogen Idec
  • BioMarin
  • Biotest Pharmaceuticals
  • Bristol-Myers Squibb
  • Catalyst Biosciences
  • China Biologic Products
  • Cosmo Pharmaceuticals
  • Kamada
  • King Pharmaceuticals
  • Medxbio
  • Merck
  • Mitsubishi Tanabe Pharma
  • Novo Nordisk
  • Novozymes
  • Portola Pharmaceuticals
  • ProMetic Life Sciences
  • rEVO Biologics
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS
  • Teva Pharmaceutical
  • The Medicines Company
  • Thermo Fisher Scientific
  • Tianjin SinoBiotech & Beijing Bio-Fortune
  • Ventria Bioscience
Market driver
  • Growing preference for marketed products over alternative treatment options.
  • For a full, detailed list, view our report
Market challenge
  • Existence of plasma fractionation supply and demand gap.
  • For a full, detailed list, view our report
Market trend
  • Increased development of recombinant products for critical care use.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Critical Care Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global critical care therapeutics market: CSL Behring, Grifols, Kedrion Biopharma, Octapharma, and Shire.

Other Prominent Vendors in the market are: Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, and Ventria Bioscience.

Commenting on the report, an analyst from Technavio’s team said: “One trend in market is establishment of plasma fractionation facilities in emerging economies by global players. Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations. However, currently the presence of plasma fractionation facilities is very much limited to China within emerging countries, but in future, the incentives listed above should be driving the vendors to establish more facilities in these regions. For instance, in 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, would drive global players to open number of such facilities in the region.”

According to the report, one driver in market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. For instance, according to the CDC 2015 report, around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year.

Further, the report states that one challenge in market is high regulations of plasma products. Manufacturers of critical care therapeutics need to follow rigorous and distinct sets of regulatory guidelines like the adherence to current good manufacturing practices (cGMP) during the donation and processing of the plasma products. These guidelines are applied both for the collection of plasma from donors and during the fractionation of plasma-derived products along with the manufacture and production of the final product. Various regulatory bodies like the WHO; European Commission Directorate-General for Health and Consumers (DG SANCO), EMA, EDQM, and NCAs in the EU; HHS, US FDA, and the CDC, in the US; and Anvisa and COFEPRIS in ROW regulate these processes. Also, the approval process for plasma products is very long. For instance, in China, the plasma products have to go through 10 different stages, which takes a minimum of 22-28 months to receive approval for commercialization in the market by the CFDA. Since the plasma collection and manufacturing units are required to follow these guidelines, which requires high cost and efficiency, many of the new players are unable to enter the market, thus hindering the market growth.

Companies Mentioned

CSL Behring, Grifols, Kedrion Biopharma, Octapharma, Shire, Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
    • The role of plasma therapeutics in critical care industry
    • Introduction to plasma therapeutics
      • Table Composition of blood
      • Table Composition of plasma
      • Table Process of procurement and manufacturing of plasma therapeutics
      • Table Regulatory policies of plasma therapeutics life cycle
    • Introduction to anticoagulants
      • Table Process of blood coagulation
      • Table Mechanism of blood coagulation
  • Global critical care therapeutics: Market landscape
    • Market overview
      • Table Market snapshot of global critical care therapeutic market
      • Table Overview of global critical care therapeutic market 2016-2021
      • Table Global critical care therapeutic market snapshot: Developed and emerging market 2016-2021
      • Table Global critical care therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis in global critical care therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Market segmentation of global critical care therapeutics by drug class
    • Global albumin market
      • Table Overview of global albumin market
    • Global prothrombin complex concentrates market
      • Table Overview of global prothrombin complex concentrates market
    • Global antithrombin concentrates market
      • Table Overview of antithrombin concentrates market
    • Global factor XIII concentrates market
      • Table Overview of global factor XIII concentrates market
    • Global fibrinogen concentrates market
      • Table Overview of global fibrinogen concentrates market
  • Market segmentation by application
    • DVT
    • Pulmonary embolism (PE)
    • Acute coronary syndrome
    • Atrial fibrillation
    • Hemodialysis
    • Coronary angioplasty
    • Surgeries
  • Geographical segmentation
    • Table Global critical care therapeutics market: Segmentation by geography 2016-2021
    • Table Global critical care therapeutics market segmentation by region: Market growth life cycle analysis 2016
    • Critical care therapeutics market in Americas
      • Table Overview of critical care therapeutics market in Americas
      • Table Critical care therapeutics market in Americas 2016-2021 ($ millions)
      • Table Opportunity analysis of critical care therapeutics market in Americas
      • Table Pest analysis of critical care therapeutics market in Americas
    • Critical care therapeutics market in EMEA
      • Table Overview of critical care therapeutics market in EMEA
      • Table Critical care therapeutics market in EMEA 2016-2021 ($ millions)
      • Table Opportunity analysis of critical care therapeutics market in EMEA
      • Table Pest analysis of critical care therapeutics market in EMEA
    • Critical care therapeutics market in APAC
      • Table Overview of critical care therapeutics market in APAC
      • Table Critical care therapeutics market in APAC 2016-2021 ($ millions)
      • Table Opportunity analysis of critical care therapeutics market in APAC
      • Table Pest analysis of critical care therapeutics market in APAC
  • Market drivers
    • Table Impact of drivers and challenges on global critical care therapeutics market
    • High demand for albumin in China
    • Increasing surgical procedures
    • Growing preference for marketed products over alternative treatment options
    • Impact of drivers
      • Table Impact of drivers
  • Market challenges
    • Existence of plasma fractionation supply and demand gap
      • Table Demand and supply gap: Plasma-derived products (million liters/year)
    • Spread of pathogenic contaminants
    • High regulations of plasma products
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Impact of trends on global critical care therapeutics market
    • Increased development of recombinant products for critical care use
    • Establishment of plasma fractionation facilities in emerging economies by global players
    • Strategic initiatives of vendors fueling the market growth
      • Table Overview of critical care therapeutics: M&A and licensing partnerships 2005-2012
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global critical care therapeutics market 2016
      • Table Competitive analysis of global critical care therapeutics market
      • Table Market penetration of various plasma products manufacturers worldwide 2016
    • Other prominent vendors
  • Key vendor analysis
    • CSL Behring
      • Table CSL Behring: Key highlights
      • Table CSL Behring: Strength assessment
      • Table CSL Behring: Strategy assessment
      • Table CSL Behring: Opportunity assessment
    • Grifols
      • Table Grifols: Key highlights
      • Table Grifols: Strength assessment
      • Table Grifols: Strategy assessment
      • Table Grifols: Opportunity assessment
      • Table Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
    • Kedrion Biopharma
      • Table Kedrion Biopharma: Key highlights
      • Table Kedrion Biopharma: Strength assessment
      • Table Kedrion Biopharma: Strategy assessment
      • Table Kedrion Biopharma: Opportunity assessment
    • Octapharma
      • Table Octapharma: Key highlights
      • Table Octapharma: Strength assessment
      • Table Octapharma: Strategy assessment
      • Table Octapharma: Opportunity assessment
    • Shire
      • Table Shire: Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report